Gender Diversity in Indian Pharma
India could boost its GDP by USD 0.7 trillion in 2025 by matching the rate of improvement of gender equality of the…
Lupin Limited is a transnational pharmaceutical company based in Mumbai. It is the 12th-largest company by market capitalization; and the eighth-largest generic pharmaceutical company by revenue globally. The company’s key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.
Lupin was founded in 1968 by Desh Bandhu Gupta, then an Associate Professor at BITS-Pilani, Rajasthan. Gupta died on 26 June 2017 and was replaced as chairman by his wife, Manju Deshbandhu Gupta.
Lupin first gained recognition when it became one of the world’s largest manufacturers of tuberculosis drugs. The company today has a significant market share in key markets in the cardiovascular (prils and statins), Diabetology, asthma, paediatrics, CNS, GI, anti-infectives and NSAIDs therapy segments. It also has a global leadership position in the anti-TB and Cephalosporin segments.
Lupin’s foray into advanced drug delivery systems has resulted in the development of platform technologies that are being used to develop value-added generic pharmaceuticals. Its manufacturing facilities, spread across India and Japan, have played a critical role in enabling the company to realise its global aspirations. Benchmarked to International standards, these facilities are approved by international regulatory agencies including the US FDA, UK MHRA, Japan’s MHLW, TGA Australia, WHO, and the MCC South Africa.
In July 2015 the company announced its intention to acquire Gavis Pharmaceuticals and Novel Laboratories for $880 million.